John K Lee

List of Publications by Citations

28 papers	966 citations	13 h-index	29 g-index
29 ext. papers	1,349 ext. citations	11.6 avg, IF	3.74 L-index

#	Paper	IF	Citations
28	N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. *Cancer Cell*, **2016**, 29, 536-547	24.3	189
27	Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. *Science*, **2018**, 362, 91-95	33.3	139
26	Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. *Cell*, **2016**, 166, 1041-1054	56.2	132
25	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. *Clinical Cancer Research*, **2019**, 25, 6916-6924	12.9	94
24	Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E4762-9	11.5	82
23	Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 4482-7	11.5	66
22	Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E4473-E4482	11.5	56
21	FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. *Modern Pathology*, **2017**, 30, 1262-1272	9.8	46
20	Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E6457-E6466	11.5	32
19	Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. *Science Translational Medicine*, **2019**, 11,	17.5	24
18	Water and glycerol permeation through the glycerol channel GlpF and the aquaporin family. *Journal of Synchrotron Radiation*, **2004**, 11, 86-8	2.4	20
17	Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. *JCI Insight*, **2019**, 5,	9.9	14
16	Shared Antigen-specific CD8+ T cell Responses Against the SARS-COV-2 Spike Protein in HLA A*02:01 COVID-19 Participants		14
15	Targeting RET Kinase in Neuroendocrine Prostate Cancer. *Molecular Cancer Research*, **2020**, 18, 1176-1188	5.6	11
14	Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer. *Clinical Cancer Research*, **2020**, 26, 1667-1677	12.9	11
13	Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer. *Clinical Cancer Research*, **2021**, 27, 759-774	12.9	9
12	Precision Medicine-Enabled Cancer Immunotherapy. *Cancer Treatment and Research*, **2019**, 178, 189-205	3.5	6

List of Publications

11	A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture. *Scientific Reports*, **2021**, 11, 4609	4.9	6
10	PEG10 Promoter-Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer. *Cancer Research*, **2019**, 79, 5668-5680	10.1	5
9	Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer. *Nature Communications*, **2021**, 12, 4789	17.4	4
8	Identification of Cell Surface Targets for CAR T Cell Immunotherapy. *Methods in Molecular Biology*, **2020**, 2097, 45-54	1.4	2
7	RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. *Cancer Research*, **2021**, 81, 4736-4750	10.1	2
6	BiTE-ing into Prostate Cancer with Bispecific T-cell Engagers. *Clinical Cancer Research*, **2021**, 27, 2675-2677	12.9	1
5	Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. *Clinical Genitourinary Cancer*, **2021**, 19, 144-154	3.3	1
4	Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 496.e1-496.e8	2.8	0
3	Epileptogenesis in Common Parasitic Infections.. *Current Neurology and Neuroscience Reports*, **2022**, 1	6.6	0
2	Development of Cancer Immunotherapies.. *Cancer Treatment and Research*, **2022**, 183, 1-48	3.5	0
1	Endoscopic ultrasound-guided transgastric drainage of a complex multiloculated peritoneal fluid collection as rare complication of lupus peritonitis. *Endoscopy*, **2016**, 48 Suppl 1 UCTN, E39	3.4	